ANRO · Alto Neuroscience, Inc.

NYSEHealthcareBiotechnology

Alto Neuroscience Inc Is A Clinical-Stage Biopharmaceutical Company With A Mission To Redefine Psychiatry By Leveraging Individual'S Neurobiology To Develop Personalized And Effective Treatment Options. The Company Currently Consists Of Different Clinical-Stage Assets Such As Alto-100, Alto-202, Alto-207, Alto-101, And Alto-300 Among Others Initially Targeting Depressive Disorders And Schizophrenia Populations As Identified By Independent Brain-Based Biomarkers.

HealthcareNYSEUSMid Float

$12.19

+94.1% latest move

Price & move as of the most recent catalyst (Oct 20) — not a live quote.

FLOAT

26.1M

FREE FLOAT %

66%

SHARES O/S

39.2M

MARKET CAP

$947.7M

EXCHANGE

NYSE

COUNTRY

ANRO Catalyst History

Financial ResultsOct 20, 2025 · 7:01am ET

ANROAlto Neuroscience, Inc.

Alto Neuroscience Announces $50M Private Placement and Phase 3 Study Plan for ALTO-207

Company aims to accelerate development in treatment resistant depression.

Be early on the next ANRO spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

ANRO · Alto Neuroscience, Inc.

ANRO Catalyst History

Alto Neuroscience Announces $50M Private Placement and Phase 3 Study Plan for ALTO-207

Alto Neuroscience Announces $50M Private Placement and Phase 3 Study Plan for ALTO-207

Alto Neuroscience Investigated for Alleged Misleading Statements

Alto Neuroscience Investigated for Alleged Misleading Statements